CR20210163A - Inhibidores de pde4 que contienen boro - Google Patents

Inhibidores de pde4 que contienen boro

Info

Publication number
CR20210163A
CR20210163A CR20210163A CR20210163A CR20210163A CR 20210163 A CR20210163 A CR 20210163A CR 20210163 A CR20210163 A CR 20210163A CR 20210163 A CR20210163 A CR 20210163A CR 20210163 A CR20210163 A CR 20210163A
Authority
CR
Costa Rica
Prior art keywords
containing boron
pde4 inhibitors
inhibitors containing
pde4
formula
Prior art date
Application number
CR20210163A
Other languages
English (en)
Inventor
Thean Yeow Yeoh
David Clive Blakemore
David Christopher Limburg
Matthew Alexander Perry
Peter Jones
Tsutomu Akama
Yasheen Zhou
Robert Toms Jacobs
Martins Sunday Oderinde
Rubben Federico Torella
Joseph Walter Strohbach
Jacob John Plattner
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68136492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20210163(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CR20210163A publication Critical patent/CR20210163A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invencion se refiere a compuestos que contienen boro de la Formula (I)X-Y-Z Formula (I) que inhiben la fosfodiesterasa 4 (PDE4). La invencion tambien comprende composiciones farmaceuticas que contienen estos compuestos y metodos para tratar enfermedades, afecciones o trastornos que mejoran mediante la inhibicion de PDE4.
CR20210163A 2018-10-05 2019-10-01 Inhibidores de pde4 que contienen boro CR20210163A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862741868P 2018-10-05 2018-10-05
US201962889599P 2019-08-21 2019-08-21
PCT/IB2019/058355 WO2020070651A1 (en) 2018-10-05 2019-10-01 Boron containing pde4 inhibitors

Publications (1)

Publication Number Publication Date
CR20210163A true CR20210163A (es) 2021-06-24

Family

ID=68136492

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210163A CR20210163A (es) 2018-10-05 2019-10-01 Inhibidores de pde4 que contienen boro

Country Status (30)

Country Link
US (3) US10946031B2 (es)
EP (1) EP3861001B1 (es)
JP (1) JP7048823B2 (es)
KR (1) KR102576125B1 (es)
CN (1) CN113166177B (es)
AU (1) AU2019351960B2 (es)
BR (1) BR112021005870B1 (es)
CA (1) CA3114702C (es)
CL (1) CL2021000843A1 (es)
CO (1) CO2021003928A2 (es)
CR (1) CR20210163A (es)
CU (1) CU20210023A7 (es)
DK (1) DK3861001T3 (es)
DO (1) DOP2021000055A (es)
EC (1) ECSP21023404A (es)
ES (1) ES2974208T3 (es)
FI (1) FI3861001T3 (es)
GE (2) GEP20227442B (es)
IL (1) IL282083B2 (es)
MA (1) MA53808A (es)
MX (1) MX2021003871A (es)
NI (1) NI202100020A (es)
PE (1) PE20211546A1 (es)
PH (1) PH12021550743A1 (es)
PY (1) PY1983118A (es)
SG (1) SG11202102674RA (es)
TW (1) TWI764052B (es)
UY (1) UY38400A (es)
WO (1) WO2020070651A1 (es)
ZA (1) ZA202101822B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100719YA (en) 2018-07-24 2021-02-25 Taiho Pharmaceutical Co Ltd Heterobicyclic compounds for inhibiting the activity of shp2
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
JP2023538362A (ja) * 2020-08-20 2023-09-07 ファイザー・インク 1(r)-4-(5-(4-メトキシ-3-プロポキシフェニル)ピリジン-3-イル)-1,2-オキサボロラン-2-オールの安定な局所製剤
EP4204012A1 (en) 2020-08-31 2023-07-05 Pfizer Inc. Methods of protecting rna
MX2023007579A (es) * 2020-12-25 2023-07-06 Reistone Biopharma Company Ltd Derivado de borato y usos del mismo.
TW202404610A (zh) * 2022-06-24 2024-02-01 大陸商瑞石生物醫藥有限公司 一種硼酸酯衍生物的結晶、其製備方法及用途
TW202408483A (zh) * 2022-06-24 2024-03-01 大陸商瑞石生物醫藥有限公司 一種硼酸酯衍生物的可藥用鹽、其結晶形式及用途
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411587D0 (en) 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
JP5038912B2 (ja) * 2005-02-16 2012-10-03 アナコール ファーマシューティカルズ,インコーポレイテッド ホウ素含有小分子
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
JP5745279B2 (ja) 2008-01-09 2015-07-08 アナコール ファーマシューティカルズ,インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
BRPI0908565A2 (pt) * 2008-03-06 2017-05-23 Anacor Pharmaceuticals Inc composto, formulação farmacêutica, métodos para reduzir a liberação de uma citocina ou de uma quimiocina, para tratar uma condição em um animal e para inibir uma fosfodiesterase
WO2012067663A1 (en) * 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
CN103857289A (zh) 2011-10-07 2014-06-11 先正达参股股份有限公司 用于保护有用植物或植物繁殖材料的方法
PL2912019T3 (pl) * 2012-10-25 2021-11-02 Tetra Discovery Partners Llc Heteroarylowe inhibitory pde4
EP2752196A1 (en) 2013-01-03 2014-07-09 Université Bordeaux Segalen Selective nox-1 inhibitor peptides and uses thereof
DK2950644T3 (en) 2013-01-30 2017-09-04 Agrofresh Inc USE OF BENZOXABOROLS AS VOLATIVE ANTIMICROBIAL AGENTS IN MEAT, PLANTS OR PARTS
WO2014147009A1 (en) 2013-03-18 2014-09-25 Syngenta Participations Ag Novel microbiocides
AU2014202928B1 (en) 2013-06-05 2014-09-11 Agrofresh Inc. Compounds and compositions
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
CN112088157B (zh) 2017-12-22 2023-12-26 拉文纳制药公司 作为磷脂酰肌醇磷酸激酶抑制剂的芳基-联吡啶胺衍生物

Also Published As

Publication number Publication date
US20230148402A1 (en) 2023-05-11
DK3861001T3 (da) 2024-01-15
CA3114702A1 (en) 2020-04-09
TWI764052B (zh) 2022-05-11
KR102576125B1 (ko) 2023-09-08
BR112021005870B1 (pt) 2024-01-09
SG11202102674RA (en) 2021-04-29
MA53808A (fr) 2022-01-12
GEP20227442B (en) 2022-11-25
CA3114702C (en) 2023-08-08
PH12021550743A1 (en) 2021-10-11
DOP2021000055A (es) 2021-05-16
CO2021003928A2 (es) 2021-04-19
US20200108083A1 (en) 2020-04-09
IL282083B1 (en) 2025-01-01
US20210069219A1 (en) 2021-03-11
PE20211546A1 (es) 2021-08-16
EP3861001A1 (en) 2021-08-11
WO2020070651A1 (en) 2020-04-09
EP3861001B1 (en) 2023-12-13
IL282083A (en) 2021-05-31
KR20210068532A (ko) 2021-06-09
BR112021005870A2 (pt) 2021-07-27
UY38400A (es) 2020-04-30
MX2021003871A (es) 2021-05-27
AU2019351960B2 (en) 2022-07-28
IL282083B2 (en) 2025-05-01
CL2021000843A1 (es) 2021-09-10
JP2021534222A (ja) 2021-12-09
AU2019351960A1 (en) 2021-04-29
FI3861001T3 (fi) 2024-01-03
ECSP21023404A (es) 2021-05-31
ES2974208T3 (es) 2024-06-26
NI202100020A (es) 2021-08-24
US10946031B2 (en) 2021-03-16
CN113166177B (zh) 2024-09-03
JP7048823B2 (ja) 2022-04-05
US11559538B2 (en) 2023-01-24
GEAP202215599A (en) 2022-08-10
TW202027755A (zh) 2020-08-01
CU20210023A7 (es) 2021-10-12
PY1983118A (es) 2021-07-15
CN113166177A (zh) 2021-07-23
ZA202101822B (en) 2022-08-31

Similar Documents

Publication Publication Date Title
ECSP21023404A (es) Inhibidores de pde4 que contienen boro
MX2020007383A (es) Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47.
ECSP24026455A (es) Compuestos de pirrolotriazina como inhibidores de tam
NI201400121A (es) Compuestos de indol e indazol que activan la ampk
UY33245A (es) Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
CU20180006A7 (es) Compuestos de indazaol y azaindazol como inhibidores de irak-4
JOP20180113B1 (ar) مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
CO2021003391A2 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
ECSP13012600A (es) CO-cristales y Sales de Inhibidores de CCR3
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
MX2019008331A (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
PH12021550258A1 (en) Cdk8/19 inhibitors
UY38133A (es) Nuevos inhibidores de cdk8/19
EA201591369A1 (ru) Новые производные пиримидина в качестве ингибиторов фосфодиэстеразы 10 (pde-10)
SA521430837B1 (ar) مركبات مثبطة لمبادل الصوديوم-الهيدروجين 3
CL2020001089A1 (es) Compuestos inhibidores de tirosina cinasa de bruton (btk).
EA202190690A1 (ru) Борсодержащие ингибиторы pde4
MA39204A1 (fr) Derives hétéroaryles inhibiteurs de vps34 et/ou de p13 pour le traitement de troubles proliferatifs, inflammatoires ou cardiovasculaires
MA44503B1 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam
EA201891687A9 (ru) Новые замещённые производные цианиндолина в качестве nik-ингибиторов
MA35151B1 (fr) Composés microarn et procédés pour la modulation de l'activité de mir-21